The effects of VIP on intestinal motility: study on ex vivo perfused isolated canine jejunal loops.
The effects of VIP on intestinal motility were studied on isolated canine jejunal loops ex vivo perfused at normothermia, under pulsatile flow with heparinized, oxygenated and nonrecirculated canine whole blood, by means of an intraluminal balloon. VIP was administered intraarterially either by 1 min injections or by long-time infusions. The results showed that for arterial concentrations of the polypeptide ranging between 25 pg/ml and 300-500 pg/ml a fast but short-lasting relaxant effect was observed. For higher concentrations VIP usually produced a biphasic response: The relaxant effect is followed by an increase of the basal muscular tone often accompanied, for concentrations higher than about 25 ng/ml, by a marked and transient increase in amplitude of the intestinal rhythmic contractions. During long-time infusions a biphasic response was also observed but both effects were of short duration. A cholingeric origin of the secondary contracting phase was expected but could not be demonstrated because, at blood concentrations at which atropine affected the biphasic response, not only was the contractile effect abolished but also the initial relaxing phase. It is suggested that the secondary contraction may be a "rebound excitation" of myogenic nature or a result of noncholingeric excitatory fiber stimulations. The short-lasting relaxant effect observed under the present experimental conditions, even during long-time infusion of the polypeptide, fails to argue for an important physiological role of VIP as an hormonal inhibitor of intestinal motility. The biphasic response, however, might have a physiological significance in so far as the aboral propulsion of the intestinal content requires a muscular inhibition which rapidly changes to contraction.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D046508:Culture Techniques; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005768:Gastrointestinal Hormones / Q000494:pharmacology*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D007583:Jejunum / Q000187:drug effects; D008365:Manometry; D009119:Muscle Contraction / Q000187:drug effects; D009126:Muscle Relaxation / Q000187:drug effects; D009129:Muscle Tonus / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects*; D010477:Perfusion; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D005768:Gastrointestinal Hormones; D014660:Vasoactive Intestinal Peptide; D001285:Atropine